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Abstract
Background: Breast cancer is the most common type of cancer among women worldwide. In low and middle-
income countries (LMICs), appropriate selection of medicines on national essential medicines lists (NEMLs) is a first step
towards adequate access to treatment. We studied selection of systemic treatments for breast cancer on NEMLs and
assessed its alignment with treatment guidelines for different types of early and advanced breast cancer. Furthermore,
influence of country characteristics on the selection was investigated.
Method: NEMLs from 75 LMICs were studied for inclusion of all components of therapy in each stage of breast cancer
according to international consensus guidelines. The results were then grouped by income level, WHO region and the
NEMLs’ release date. Non parametric tests were used for statistical analysis.
Results: Unlike HER2-targeted therapies (<10 %), aromatase inhibitors (12 %) and taxanes (28 %); tamoxifen and first
generation chemotherapeutic regimens (e.g., anthracycline-based regimens) were frequently found in the NEMLs
(71–78 %). Consequently, all components of treatment for “Luminal A” early breast cancer and non HER2 overexpressed
advanced breast cancer were found on the NEMLs of over 70 % of countries. However, 40 % of the low income
countries did not have all the components of therapy for any type of early breast cancer in their NEMLs, and adequate
treatment of HER2 overexpressed breast cancer was hardly possible with the current selections. Recent NEMLs were
more aligned with the guidelines (p < 0.05). Eastern Mediterranean and African regions less frequently incorporated all
components of breast cancer treatment in their NEMLs.
Conclusion: Alignment of selection with guidelines’ recommendations was inconsistent for different types of early and
advanced breast cancer in NEMLs. Regular updates and more attention to clinical guidelines is therefore
recommended.
Background
Breast cancer is the leading cause of death among
women in both developed and developing countries [1].
Substantial progress has been made in the past decades
in early detection, screening and treatment of breast
cancer. This has resulted in 5-year survival rates of ap-
proximately 80 %, 60 % and 40 % for high, middle and
low income countries, respectively [2]. Comprehensive
national cancer control plans to fight (breast) cancer
may consist of prevention, screening and early detection,
diagnosis, treatment (surgery, radiotherapy and systemic
therapy) and palliative care [3]. Not necessarily all the
components of a comprehensive national cancer control
plan exist in every low or middle income country
(LMIC). In some cases existence and accessibility of fa-
cilities for surgery and radiotherapy have even been
questioned [4–6].
Little is known about global access to systemic therapy
as a part of the treatment of breast cancer. Many inter-
national guidelines have been published including guide-
lines adjusted for resource constrained countries or
geographical regions [5–12]. However, availability of rec-
ommended therapies according to the guidelines has
hardly ever been evaluated although sporadic reports re-
garding low availability of human epidermal growth fac-
tor receptor type 2 (HER2)- targeted therapies in LMICs
have been published [13].
Selection of appropriate medication for breast cancer
on national essential medicines lists (NEMLs) is an
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initial step in achieving adequate access to pharmaco-
logical treatment in LMICs. Essential medicines are
those that satisfy the priority health care needs of the
population [14]. They are selected with due regard to
disease prevalence, evidence on efficacy and safety, and
comparative cost-effectiveness and have an established
role in public procurement or reimbursement of medi-
cines in the majority of LMICs. Over 90 % of surveyed
LMICs are reported to use their NEML for public pro-
curement of medicines [14]. Consequently, being listed
as essential medicine can be seen as a prerequisite for
access to a medicine in clinical practice, particularly in
the public sector of LMICs where the majority of pa-
tients would primarily seek their treatment.
Selection of essential medicines for oncology is sub-
optimal for newer therapies but more strikingly for con-
ventional therapies and in particular for hormonal
therapies across LMICs [15]. As the latter group of med-
icines plays a pivotal role in breast cancer treatment, we
thoroughly studied available NEMLs to assess diversity
in selection of breast cancer medicines across LMICs.
Besides, we aimed to assess the extent to which these se-
lected essential medicines would allow treatment of dif-
ferent stages of breast cancer according to international
treatment guidelines. The influences of country income
level, geographic region and year of update of the NEML
on the selection were also explored.
Methods
Data collection and classification
Essential medicines lists
NEMLs from LMICs were obtained in May 2013 from
the “WHO database of essential medicine lists and for-
mularies” [16]. The latest available update of the NEMLs
was considered for each country. Countries with a
NEML dated prior to 2005 were excluded (n = 6). Since
the WHO has recommended countries to periodically
update their NEMLs, this measure was taken to ensure
that only dynamic lists were considered for this study
[14]. In China, provincial EMLs were deemed eligible
and were added to make an EML list, instead of the
NEML, since no essential oncology medicines were
found on the NEML of China [17]. Eventually, 75 coun-
tries were included in the analysis which were represen-
tative of the low and middle income levels across all
WHO regions (see Additional file 1: Annex 1).
Medicines were included in the study if they were cat-
egorized as oncology medicines in the NEML (or equiva-
lent terms in different NEMLs or languages). Palliative
and supportive therapies and medicines for management
of side effects and complications were excluded. Of the
remaining medicines, only those which were recom-
mended for breast cancer according to international
guidelines (see below) were included. Medicines used for
breast cancer are generally categorized into three differ-
ent classes, namely chemotherapeutic agents, endocrine
therapy agents and HER2-targeted therapies. Chemo-
therapeutic agents have a non-selective cytotoxicity and
are indicated in different types of malignancies. Endo-
crine therapy agents play a crucial role in treatment of
hormone receptor (estrogen and/or progesterone) posi-
tive breast cancer patients [18]. HER2-targeted therapies
are shown to increase overall survival in patients with
HER2-overexpressing tumors through blockage of extra-
cellular or intracellular components of the HER2 protein
[19, 20].
Therapeutic guidelines
PubMed was searched to obtain the most recent updates
(at the time of study, i.e., July 2013)) of evidence based
international consensus guidelines for different stages of
breast cancer. Precedence was given to guidelines de-
signed for LMICs when various guidelines were avail-
able. Eventually the guidelines were classified into two
main groups: (1) Guidelines in which the consensus was
based on different types of disease or tumor [7, 8, 11]
and (2) Guidelines in which the consensus was formu-
lated for different levels of care (based on available re-
sources and services) [4–6, 9, 10, 12, 21]. These latter
guidelines were mainly based on the Breast Health Glo-
bal Initiative (BHGI) consensus for LMICs modified for
implementation in different situations (e.g., different in-
come levels of countries or different regions). As the ini-
tial interest of the current study was to investigate which
stages of disease and which tumor types can be treated
with the selected medicines, the first group of guidelines
was selected for the final analyses (namely: St. Gallen
International Expert Consensus on the Primary Therapy
of Early Breast Cancer [7] and 1st International consen-
sus guidelines for advanced breast cancer (ABC 1) [8]).
Different subtypes of early and advanced breast cancer
-according to the guidelines- are described in Table 1.
For each type of breast cancer, the necessary compo-
nents of treatment regimens were identified based on
the aforementioned guidelines. Full details of all compo-
nents for treatment of breast cancer are given in
Additional file 1: Annex 2.
Other sources of data
Data on geographic regions and income levels were ob-
tained from the WHO and the World Bank, respectively
[22, 23].
Data analysis
First, the frequency of inclusion of breast cancer medi-
cines and combinations (chemotherapeutic or endocrine
therapy) as recommended by the international guidelines
in different NEMLs were calculated. Then the NEMLs
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were assessed to see if all components of a particular
treatment regimen as mentioned in the therapeutic guide-
lines could be collectively found for each stage of disease
and each type of tumor. In all cases, only classes of medi-
cines - as recommended by the guidelines - were consid-
ered, regardless of the number of medicines within each
class being designated as essential medicine. The propor-
tion of countries which selected a complete therapeutic
regimen was then calculated for each type and stage of
disease. Data were subsequently stratified and analyzed ac-
cording to different income levels and WHO regions.
Moreover, in order to compare the extent of compliance
with the international guidelines between newer and older
NEMLs, the NEMLs released in 2009 and afterwards were
compared with the ones published prior to 2009.
When the frequency or percentage of inclusion of treat-
ments in the NEMLs for various types of breast cancer
was compared between different clusters of countries,
non-parametric tests were used to investigate the differ-
ences among groups, namely the Kruskal Wallis test for
geographic regions and income levels as well as the Chi
square test for recent versus older NEMLs. All statistical
analyses were conducted using SPSS software, version 19.
Research ethics statement as requested by the journal
was not applicable to our study. All the data used in the
manuscript is freely available.
Results
Selection of essential medicines for breast cancer
Overall, 84 % and 74 % of the studied countries had at
least one chemotherapeutic and one hormonal agent for
breast cancer, respectively. Slightly fewer than 10 % of
the countries had a HER2-targeted therapy as essential
medicine.
Figure 1 shows the inclusion of the main chemothera-
peutic and hormonal regimens for the treatment of
breast cancer according to the international guidelines
in the NEMLs. Tamoxifen, anthracylines, CMF (cyclo-
phosphamide, methotrexate and fluorouracil), CAF
(cyclophosphamide, doxorubicin and fluorouracil) and
AC (doxorubicin and cyclophosphamide) were well rep-
resented with inclusion in more than 70 % of the
NEMLs as opposed to inclusion in below 30 % for all
other main regimens.
A more detailed overview of inclusion of individual
chemotherapeutic and hormonal agents is illustrated in
Additional file 1: Annex 3. Cyclophosphamide, metho-
trexate, fluorouracil and tamoxifen were found in over
75 % of the NEMLs, and doxorubicin and vinblastine in
over 50 %. Of the HER2-targeted therapies, lapatinib
was completely absent and trastuzumab was selected in
less than 10 % of the NEMLs.
Selection of treatment regimens for different breast
cancer stages
Early breast cancer
In three out of four of the studied countries all compo-
nents for treatment of “Luminal A” type breast cancer
were selected as essential medicines. One third of the
countries also had all components for the treatment of the
“triple negative” type. One in four countries had all com-
ponents for treatment of four different types including
Table 1 Different subtypes of early and advanced breast cancer according to the selected guidelines (7, 8)
Type of breast cancer Subtypes Descriptions
Early breast cancer† Luminal A HR+;HER2-; Ki-67 low
Luminal B HR+;HER2-; Ki-67 high
Non luminal HR+;HER2+; Ki-67 low
Triple negative (ductal) HR absent; HER2 absent
Special histological types HER2 absent; endocrine responsive or non-responsive




HR+ = ER and/or PR positive tumor, HR- = ER and/or PR negative tumor, HER2 human epidermal growth factor receptor type 2 oncogene, HER2+ = HER2 over
expressed or amplified, HER2- = not HER2+, Ki-67 a marker of cell proliferation
†Early breast cancer: Breast cancer that has not spread beyond the breast or the axillary lymph nodes. This includes ductal carcinoma in situ and stage I, stage IIA,
stage IIB, and stage IIIA breast cancers. (Reference: National Cancer Institute; http://www.cancer.gov/dictionary?cdrid=446564)
††Advanced breast cancer: Breast cancer that has spread locally in the area of the breast (locally advanced breast cancer) or to distant organs and tissues
(metastatic breast cancer), it includes: •Stage III: the cancer has either extensively spread to lymph nodes and/or other tissue in the area of the breast, but not to
distant sites in the body •Stage IV: the cancer has spread to distant sites of the body, such as the liver, lungs, bones, brain, and/or other sites (Reference: advanced
breast cancer community; http://www.advancedbreastcancercommunity.org/advanced-breast-cancer/defining-advanced-breast-cancer.html)
†,††: Early breast cancer is classified based on clinicopathological criteria namely detection of the estrogen receptor, progesterone receptor, over expression or
amplification of the HER2 oncogene and Ki-67 labeling index (a marker of cell proliferation). Advanced breast cancer is classified in a similar way except for the
Ki-67 labeling index which has no role in this classification
(Reference: a) Goldhirsch A, et al. Ann Oncol 2011 Aug;22(8):1736–1747. b) Cardoso F, et al. Breast 2012 Jun;21(3):242–252.)
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“Luminal B (HER2-)” and “Special histological types” of
early breast cancer in addition to the former two types. All
treatment components (collectively) for HER2+ tumors
were only found in less than 10 % of the NEMLs.
Figure 2a shows that inclusion of essential medicines
was constantly more aligned with the therapeutic guide-
lines in middle income countries compared to low in-
come countries (p = 0.047). Forty percent of the low
income countries did not have all therapy components
for any type of early breast cancer.
There was a significant difference across regions in the
proportion of countries which had all treatment compo-
nents for different types of early breast cancer in their
NEMLs (p < 0.001). While over 80 % of the American
countries included all therapy components for all types
of early breast cancer (except for HER2 overexpressed
tumors), over 40 % of the countries in the Eastern Medi-
terranean and African regions did not have all treatment
components for any subtype (Fig. 2b).
Across the different types of early breast cancer, newer
NEMLs had more frequently incorporated all treatment
components compared to the older NEMLs. However,
the difference was only statistically significant for “Lu-
minal A” type (87 % for newer NEMLs vs. 62 % for older
NEMLs, p = 0.033)
Advanced breast cancer
All components for treatment of two types, namely
HR-/ HER2- and HR+/ HER2- could be found in over
70 % of NEMLs. In contrast, all components for therapy
of HER2+ tumors (regardless of HR status) were found
in less than 10 % of the NEMLs studied.
The proportion of countries in which all components of
1st line therapy were selected in the NEMLs for different
types of advanced breast cancer was not significantly
different across the 3 income level categories (p = 0.410).
Over half of the countries in all different income levels
had all components for 1st line therapy of HR+/HER2-
and HR-/ HER2- types of advanced breast cancer as essen-
tial medicines (Fig. 3a).
However, the proportion varied significantly across re-
gions (p = 0.017). Above 85 % of the countries in the re-
gions of the Americas, Europe and South-East Asia had
all components for therapies of advanced breast cancer
(except HER2+), while -on average- 40 % of the countries
in the Eastern Mediterranean region and Africa did not
have those (Fig. 3b). Unlike in other regions, countries in
the Western Pacific region included all treatment compo-
nents for HR-/HER2- breast cancer treatment less fre-
quently than for HR+/HER2- treatment (33 % vs. 92 %).
Across all different tumor types, newer NEMLs had
more frequently incorporated all components of treat-
ments compared to the older ones. The difference was
only statistically significant for HR+/HER2- and HR-/
HER2- tumor types (87 % and 87 % for newer NEMLs
vs. 62 % and 54 % for older NEMLs, p = 0.033 and 0.005,
respectively)
Three out of four countries had all components for
2nd line treatment of HR+/HER2- type advanced breast
cancer as essential medicines. All components for 2nd
line therapy for HR+/HER2+ type of advanced breast
cancer were not found in any of the NEMLs.
The differences observed across income level categor-
ies and WHO regions and between newer and older
NEMLs were almost identical to the first line treatment
for HR+ and HER2+ types.
Discussion
Despite substantial progress made in its treatment possi-


























Fig. 1 Inclusion of main chemotherapeutic and hormonal therapy regimens in NEMLs (n = 75). CMF: cyclophosphamide, methotrexate and
fluorouracil; CAF: cyclophosphamide, doxorubicin (adriamycin), fluorouracil, AC: doxorubicin and cyclophosphamide; EC: epirubicine and
cyclophosphamide; CEF: cyclophosphamide, epirubicine and fluorouracil; DCa: docetaxel and carboplatin; DC: docetaxel and cyclophosphamide;
AIs: Aromatase Inhibitors
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This might be due to lack of access to different compo-
nents of care including systemic therapy. Selection of es-
sential medicines was explored in this study as a
prerequisite of access to medicines. First generation che-
motherapies were frequently found in the NEMLs of the
studied countries (>70 %). Endocrine therapy was also
well represented with tamoxifen being included in 75 %
of the NEMLs, whereas treatment of HER2 overex-
pressed tumors (in both early and advanced stages) was
hardly possible with the selected essential medicines. Ex-
cept for luminal A breast cancer, selection of essential
medicines did not allow treatment of early breast cancer
subtypes in many LMICs. Guideline- recommended
treatments were less frequently included in the NEMLs
of low income countries than in middle income coun-
tries. In advanced breast cancer, all components of ther-
apy (except for HER2-targeted therapies) were included
in over half of the NEMLs with no significant differences
across income levels. Compared to the other regions, the
Eastern Mediterranean and African regions less fre-
quently incorporated full breast cancer treatment
components for both early and advanced breast cancer.
Across all different breast cancer types, newer NEMLs
were more frequently aligned with clinical guidelines.
Considering the fact that breast cancer is the most bur-
densome type of cancer among women, the selection of
therapies for different disease stages is suboptimal. Treat-
ments for late stages were more frequently selected as es-
sential medicines compared to (several) early stages. In
early breast cancer, treatment was mainly absent for lu-
minal B (HER2-) in low income countries and for triple
negative and special histological types in low and lower
middle income countries. This finding can be interpreted
as a rational response to health care priorities of resource-
constrained countries. Due to lack of screening programs,
diagnostic facilities, routine checkups and cultural barriers
for educating women for self-examinations, breast cancer
is usually diagnosed at late stages in low income countries
[5, 12, 24, 25]. In addition, low income countries have to
prioritize their decisions, owing to their very limited
health care budgets which hardly exceeded an average of
































































Fig. 2 a Inclusion of all components of treatment for different types of early breast cancer tumors in the NEMLs across different income levels
number of countries: Low income n = 20; Lower middle income n = 33; Upper middle income n = 18. b Inclusion of all components of treatment
for different types of early breast cancer tumors in the NEMLs across different WHO regions number of countries: Africa n = 26; America n = 14;
Eastern Mediterranean n = 12; Europe n = 5; South-East Asia n = 8; Western Pacific n = 12
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The choice of chemotherapeutic regimens - which were
included to a relatively high extent in the NEMLs - might
have been heavily influenced by the WHO model list of
essential medicines. This can explain the absence of epiru-
bicine based regimens in the majority of the NEMLs stud-
ied, since epirubicine is absent in the WHO model list
[27, 28]. The only major deviation from the WHO model
list are taxanes which have a low rate of inclusion in the
NEMLs despite being listed by the WHO. This might be
attributable to their late inclusion in the WHO model list
in 2011; it needs additional time before medicines appear
on the majority of NEMLs. Besides, in the years prior to
2011, affordability of taxanes was of concern for health-
care systems in LMICs [29–31].
Inclusion of aromatase inhibitors’ (AIs) was low com-
pared to tamoxifen. The cost of AIs might have ham-
pered their selection despite their therapeutic benefits
[4]. In recent years patent protection of some AIs ex-
pired and a price decline was already observed [32]. Sub-
sequently LMICs may consider AIs for inclusion on
their NEML as the affordability concern is fading away.
In addition, a careful trade off may need to be made by
policymakers in view of the limited resources, whether
priority should be given to additional hormonal therap-
ies. HR+ breast cancer corresponds to the majority of
breast cancer cases and thus has a crucial role in treat-
ment. However the magnitude of benefit gained by sub-
stitution of AIs with Tamoxifen in post-menopausal
patients may need to be compared with that of adding a
HER-2 targeted therapy to the current practice in a
smaller group of patients.
A very low rate of inclusion of “all components” of
treatment for HER2 overexpressed types of breast cancer
(which constitute nearly one fourth of all cases [33]) in
the NEMLs in both stages was evident. This was mainly
due to the absence of HER2-targeted therapies while pa-
tients may still benefit from favorable effects of chemo-
therapy regimens. For inclusion of HER2-targeted
therapies a great deal of controversy should always be
addressed, even in developed countries. The percentage
of patients with HER2 overexpression may vary across
LMICs and the information is lacking in many of these
jurisdictions. The massive economic burden incurred to


































































Fig. 3 a Inclusion of all components of treatment for different types of advanced breast cancer in the NEMLs across different income levels
number of countries: Low income n = 20; Lower middle income n = 33; Upper middle income n = 18. b Inclusion of all components of treatment
for different types of advanced breast cancer in the NEMLs across different WHO regions number of countries: Africa n = 26; America n = 14;
Eastern Mediterranean n = 12; Europe n = 5; South-East Asia n = 8; Western Pacific n = 12
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recent reports of resistance against therapy are examples
of these controversies [34–37]. Besides, molecular diag-
nostic tests for appropriate patient selection are often
not integrated in routine daily practice in LMICs due to
the lack of resources and equipment [38]. Trastuzumab
was first approved over 1.5 decade ago, and its patent
will expire soon which will provide an opportunity for
better access to the medicine for patients in LMICs [39].
Due attention to the rational use of trastuzumab will re-
main a concern even when inclusion in the NEMLs will
become feasible.
Rank of breast cancer (in terms of incidence and mor-
tality among all cancer types in women) in eastern
Mediterranean and African regions is comparable with
the global pattern [1]. Other priorities in those health
care systems might have hindered inclusion of breast
cancer medicines in the NEMLs in those regions. The
main common diseases to tackle in those regions are
lower respiratory infections, diarrheal disease, preterm
birth complications and tuberculosis as well as malaria
and HIV/AIDS for the African and cardiovascular dis-
ease for the Eastern Mediterranean regions [40, 41].
This study has some limitations. While the most re-
cent breast cancer guidelines -at the time of survey
-were studied, the majority of the NEMLs investigated
were dated prior to these guidelines. However, the latest
available update of a NEML should be considered valid
until revision. Our analysis was based on international
consensus guidelines while clinical practice might vary
across and within the studied countries. Treatment of
secondary metastasis (e.g., treatment of bone and brain
metastasis), palliative care and medicines for manage-
ment of adverse events and side effects were not in-
cluded in our study, despite their essential role in the
course of treatment. In addition, as previously men-
tioned, pharmacotherapy is only one component of
breast cancer care. In the entire procedure of treatment
of breast cancer a substantial degree of disparity in ac-
cess and quality of care might be observed [42]. For ex-
ample in some countries in Africa estrogen receptor
identification is not yet routinely accessible [43]. A sys-
temic approach to explore availability of all contributing
elements of care for breast cancer, would be a next step
for further study.
Although guidelines for management of breast cancer
in LMICs have been published in literature, to our
knowledge this study is the first global study attempting
to explore decisions made for selection of systemic ther-
apy of breast cancer in LMICs, which in turn may have
direct implications for the availability of medicines for
treatment of breast cancer. Previous research showed
that in general essential medicines selected on NEMLs
were more available than those not selected as essential
medicines, highlighting the importance of adequate
selection to ensure optimal access [44]. It is of prime
priority to conduct direct availability studies on oncology
medicines in LMICs to confirm these findings.
Conclusion
First generation chemotherapeutic agents and tamoxifen
were selected as essential medicines for breast cancer
treatment on NEMLs by the vast majority of LMICs.
HER2-targeted therapies for treatment of HER2+ tumors
and taxanes were notably absent in the majority of
NEMLs. Attention to treatment guidelines can assist
countries to select essential medicines, which allow
treatment of more types and stages of breast cancer.
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